Search

IntroductionThe present study aimed to investigate the interaction of the common lncRNA-miRNA-mRNA network involved in signaling pathways in different stages of prostate cancer (PCa) by using bioinformatics and experimental methods.MethodsSeventy subjects included sixty PCa patients in Local, Locally Advanced, Biochemical Relapse, Metastatic, and Benign stages, and ten healthy subjects were entered into the current study. The mRNAs with significant expression differences were first found using the GEO database. The candidate hub genes were then identified by analyzing Cytohubba and MCODE software. Cytoscape, GO Term, and KEGG software determined hub genes and critical pathways. The expression of candidate lncRNAs, miRNAs, and mRNAs was then assessed using Real-Time PCR and ELISA techniques.Results4 lncRNAs, 5 miRNAs, and 15 common target genes were detected in PCa patients compared with the healthy group. Unlike the tumor suppressors, the expression levels of common onco-lncRNAs, oncomiRNAs, and oncogenes showed a considerable increase in patients with advanced stages; Biochemical Relapse and Metastatic, in comparison to the primary stages; Local and Locally Advanced. Additionally, their expression levels significantly increased with a higher Gleason score than a lower one.ConclusionIdentifying a common lncRNA-miRNA-mRNA network associated with prostate cancer may be clinically valuable as potential predictive biomarkers. They can also serve as novel therapeutic targets for PCa patients.

Carcinoma of the uterine cervix is the sixth most common malignant neoplasm in women worldwide. Early stage diagnosis increases the cure rate of disease. Radiotherapy with or without concurrent chemotherapy is one of the most effective treatment modalities. After radiotherapy, accurate and regular follow-up results in early diagnosis and effective treatment of recurrence.In this retrospective study, we evaluated 346 cases of cervical carcinoma who have been treated with radiotherapy in the Radiation Oncology Department of the Cancer Institute of Imam Khomeini hospital from 1995 to 2001.Age of the study group ranged from 26 to 78 (mean=50.5, SD=11). 30.4 percent of patients were early stage and 69.6 percent had advanced stage of disease. Some 92.2 percent of cases were squamous cell carcinomas and adenocarcinomas made up the 6.4 percent . Radical radiotherapy was most frequent radiotherapy setting and adjuvant radiotherapy (post-op) was the second. Most of the patients (43.7 percent) were followed for a short time, and a considerable number did not return for follow-up.According to our results, patients do not pay enough attention to disease follow-up. An acceptable training plan, with emphasis on regular follow-up, is recommended.